AccuMetab™ Human CYP2C19 Enzyme, Catalytically Active with Cytochrome b5

CAT#: ITS-0426-YL71
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Enhanced human CYP2C19 for high-activity Phase I metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Augmenting CYP2C19 with Cytochrome b5 ensures maximal catalytic velocity during the in vitro metabolism of critical therapeutics. This enhanced format is ideal for high-throughput Phase I screening and the precise generation of drug metabolites for structural identification.
Key Features
Cytochrome b5 supplemented for max catalytic turnover; Ideal for high-yield metabolite generation and LC-MS; Rapid Phase I turnover for structural identification; Available in multiple reductase ratios
Applications
Enhanced Drug Metabolism Studies, MetID, DDI
Research Areas
ADME; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry